A Real-World Experience With First-Line RTOG 0227 (Methotrexate, Temozolomide, and Rituximab) Induction for Primary CNS Lymphoma
Clinical Lymphoma, Myeloma & Leukemia
· Elsevier
Аннотация
Publication date: Available online 7 October 2026 Source: Clinical Lymphoma Myeloma and Leukemia Author(s): James J. Fradin, Ramsha Ahmed, Precious Anyanwu, Ryan Conrardy, Aniko Szabo, Nirav N. Shah, Mehdi Hamadani, Walter Longo, Julie Pruett, Jennifer Connelly, Joseph Bovi, Malika Siker, Christopher Schultz, Sumana Devata, Timothy S. Fenske
Читать у издателя →
Цитировать
Получайте новые статьи по теме «Гематология»
Подписка, поиск по ключевым словам и избранное — в Telegram-боте Articlium.
Открыть в Telegram
Цитирование
✕
ГОСТ
APA
MLA
BibTeX
A Real-World Experience With First-Line RTOG 0227 (Methotrexate, Temozolomide, and Rituximab) Induction for Primary CNS Lymphoma. // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S2152265026039984?dgcid=rss_sd_all
A Real-World Experience With First-Line RTOG 0227 (Methotrexate, Temozolomide, and Rituximab) Induction for Primary CNS Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S2152265026039984?dgcid=rss_sd_all
“A Real-World Experience With First-Line RTOG 0227 (Methotrexate, Temozolomide, and Rituximab) Induction for Primary CNS Lymphoma.” Clinical Lymphoma, Myeloma & Leukemia.
@article{article88844,
title = {A Real-World Experience With First-Line RTOG 0227 (Methotrexate, Temozolomide, and Rituximab) Induction for Primary CNS Lymphoma},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S2152265026039984?dgcid=rss_sd_all}
}